In vivo microdialysis was used to analyze the role of dorsal raphe nucleus (DRN) neurons in regulating the sleepwaking cycle. Measurements of extracellular serotonin (5HT) were made in the DRN of freely moving adult cats before and during microdialysis perfusion of 8-hydroxy-2-(di-npropylamino)tetralin (8-OH-DPAT), a selective 5-HT,, receptor agonist, in artificial CSF. Behavioral state alterations were measured by simultaneous polygraphic recordings. During waking and artificial CSF perfusion of probes histologically localized to the DRN, extracellular 5-HT was 4 fmoV7.5 ~1 dialysate sample. With the addition of 8-OH-DPAT (10 PM in artificial CSF) to the perfusate, 5-HT levels in the same state decreased 50%, to 2 fmol/sample (p < O.Ol), presumably through 5-HT,, autoreceptor-mediated inhibition of serotonergic neural activity. Concomitantly, this 8-OH-DPAT perfusion produced a short latency, threefold increase in rapid eye movement (REM) sleep, from 10 to 30% of the total recorded time (p < 0.05), whereas waking was not significantly affected. In contrast, and suggesting DRN specificity, 8-OH-DPAT delivery through a probe in the aqueduct did not increase REM sleep but rather tended to increase waking and decrease slow wave sleep.
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In vivo microdialysis was used to analyze the role of dorsal raphe nucleus (DRN) neurons in regulating the sleepwaking cycle. Measurements of extracellular serotonin (5HT) were made in the DRN of freely moving adult cats before and during microdialysis perfusion of 8-hydroxy-2-(di-npropylamino)tetralin (8-OH-DPAT), a selective 5-HT,, receptor agonist, in artificial CSF. Behavioral state alterations were measured by simultaneous polygraphic recordings. During waking and artificial CSF perfusion of probes histologically localized to the DRN, extracellular 5-HT was 4 fmoV7.5 ~1 dialysate sample. With the addition of 8-OH-DPAT (10 PM in artificial CSF) to the perfusate, 5-HT levels in the same state decreased 50%, to 2 fmol/sample (p < O.Ol), presumably through 5-HT,, autoreceptor-mediated inhibition of serotonergic neural activity. Concomitantly, this 8-OH-DPAT perfusion produced a short latency, threefold increase in rapid eye movement (REM) sleep, from 10 to 30% of the total recorded time (p < 0.05), whereas waking was not significantly affected. In contrast, and suggesting DRN specificity, 8-OH-DPAT delivery through a probe in the aqueduct did not increase REM sleep but rather tended to increase waking and decrease slow wave sleep.
The data on REM sleep provide the first biochemically validated and direct evidence that suppression of DRN serotonergic activity increases REM sleep, and furnish a key complement to our laboratory's in vitro data indicating that mesopontine cholinergic neurons, a target of DRN projections, are inhibited by 5-HT. The 8-OH-DPAT-induced reduction of DRN 5-HT is consistent with the hypothesis that the concomitant REM sleep disinhibition is mediated by DRN serotonergic projections to mesopontine cholinergic neurons, which other data implicate in REM sleep production.
Key words: 5-UT; dorsal raphe nucleus; 8-OH-DPAT; REM sleep; brainstem; microdialysis Serotonin (5-HT) has been implicated in control of many behaviorally related neural systems, including those for sleep (Steriade and McCarley, 1990) , sex (Meston and Gorzalka, 1992) , aggression (Coccaro, 1992; Olivier and Mos, 1992) , mood (Soubrie, 1988) , thermoregulation (Myers, 1980) , motor activity (Thornton, 1978; Williams and Amitia, 1981) , feeding (Blundell, 1977; Nicolaidis, 1986) , pain modulation (Le Bars, 1994) , endocrine regulation (Montange and Calas, 1988) , and learning and memory (McEntee and Crook, 1991) . With respect to changes in discharge rates of presumptively serotonergic dorsal raphe nucleus (DRN) neurons, in vivo physiological recordings have shown that the most dramatic alteration is associated with sleep: there is a virtual cessation of discharge of the entire neuronal population as the animal approaches and enters the rapid eye movement (REM) phase of sleep (McGinty and Harper, 1976; Trulson and Jacobs, 1979; Cespuglio et al., 1981; Lydic et al., 1987) . This inverse correlation with REM sleep quite early led to the suggestion that serotonergic activity might suppress REM sleep. Together with evidence for a similar time course of activity of presumptively noradrenergic locus coeruleus neurons , it led to the inclusion of monoaminergic, including serotonergic, inhibition of REM-promoting cholinergic neurons as a fundamental postulate of a structural and mathematical model of REM sleep . This postulate was originally regarded as extremely controversial. However, interest has been quickened by the following: the recent documentation of serotonergic projections from the dorsal raphe to the mesopontine cholinergic neurons in the laterodorsal (LDT) and pedunculopontine (PPT) tegmental nuclei that are implicated in the production of REM sleep (Honda and Semba, 1994) ; the in vitro demonstration of serotonergic inhibition of mesopontine cholinergic neurons by our laboratory and others (Luebke et al., 1992; Leonard and Llinas, 1994) ; and the report that microinjection of a serotonergic .5-HT,, agonist into the PPT inhibits REM sleep (Sanford et al., 1994) .
We have shown recently that the level of 5-HT release in the cat DRN parallels the time course of presumptively serotonergic neuronal activity: waking (W) > slow wave sleep (SWS) > REM sleep (Portas and McCarley, 1994) . These results also implied, we suggested, that the level of 5-HT release measured in the dorsal raphe should index the release level at other axonal projection sites, including the mesopontine cholinergic nuclei. Supporting this assumption was the earlier demonstration that 5-HT levels at distant DRN projection sites had the same behavioral state ordering of levels as those in the DRN: W > SWS > REM sleep (in cats: Wilkinson et al., 1991; in rats: Auerbach et al., 1989; Imeri et al., 1994) .
The present study was designed to test, in freely moving cats, the hypothesis of serotonergic inhibition of REM sleep. It took advantage of the evidence indicating that axon collaterals of DRN serotonergic neurons inhibit this same DRN population via somatodendritic 5-HT,, receptors (Sprouse and Aghajanian, 1987) . Thus, introduction of a selective 5-HT,, receptor agonist in the DRN via microdialysis perfusion should, we predicted, produce strong inhibition of serotonergic neural activity, which would be indicated by a reduction of 5-HT release in the DRN. We further predicted that, if the hypothesis of serotonergic inhibition of REM-promoting neurons were correct, the inhibition of DRN serotonergic activity should disinhibit REM-promoting neurons, producing a increase in REM sleep concomitant with the changes in DRN extracellular 5-HT.
MATERIALS
AND METHODS Experimental design considerations. The 5-HT,, agonist 8-hydroxy-2-(din-propylamino) tetralin (S-OH-DPAT) was selected because of its being the most specific agonist for this receptor (Arvidsson et al., 1981; Gozlan et al., 1983; Middlemiss and Fozard, 1983; Glennon et al., 1988) . There were several reasons for choosing the DRN as the localized perfusion site. First, the DRN contains -40% of the total 5-HT neurons present in the cat brainstem (Wiklund et al., 1981) . Second, activation of the .5-HT,, receptors widely distributed throughout the mammalian brain, such as would occur with systemic injections, would likely lead to complex and, for the present study, undesirable effects that have been documented in rats: the 5-HT behavioral syndrome with increased motor activity (Higgins et al., 1988) , hypothermia (Bill et al., 1991) , elevation of plasma adrenocorticotrophic hormone level (Gilbert et al., 1988) , increased sexual activity (Ahlenius et al., 1981) , and wakefulness (De St. HilaireKafi et al., 1987; Monti et al., 1990) . Lebrand et al. (1994) recently reported that this effect is especially pronounced in the rats whose S-HT,, somato-dendritic receptors were eliminated by a selective neurotoxic drug, further suggesting that the wakefulness-inducing effects of 5-HT were mediated by non-DRN sites. Furthermore, Quattrochi et al. (1993) showed a total suppression of REM sleep and ponto-geniculateoccipital (PGO) activity in cats after intravenous administration of a 5-HT, agonist, eltoprazine (2-4 mgikg) (nonspecific for 5-HT,, receptors) whereas total waking was unaltered. Third, the experiments of Adell and coworkers in rat (Adell et al., 1991 (Adell et al., , 1993 indicated that placing the probe "in the vicinity" of both the DRN and median raphe nuclei and perfusing with low levels (10 FM) of 8-OH-DPAT did not affect in vivo 5-HT microdialysate levels. Finally, using low level, microdialysis delivery of 8-OH-DPAT appears important, because administration of high doses of 5-HT via microinjection in or near the DRN in rats elicited heterogeneous behavioral responses, compatible with spread to non-DRN sites: Higgins et al. (1988) reported an increase of "social interaction" and motor activity with DRN injections of 20-200 ng in 0.5 ~1, corresponding to a concentration of 120-1200 pM. Hutson et al. (1986) observed an increase of food intake after injection of 1 pg in 0.5 ~1 in the DRN, corresponding to a concentration of 6 mM. It appears that, in both cases, waking was increased (as with systemic injections). In contrast with these results, Mos et al. (1993) reported, in rats, reduced aggressivity, reduced social interaction and increased inactivitv after 8-OH-DPAT (1 or 10 kg/OS ~1, corresponding to a concentrafion of 6-60 mM) wa's locally injected in the DRN, and Monti and Jantos (1992) reported that injections of l-4 Fg in 0.5 ~1 in the DRN (corresponding to a final concentration of 6-24 t?IM) increased SWS and decreased W, whereas REM was either not affected or was decreased at the lowest dose. The high concentration and rapid application of local injections may lead to activation of non-DRN 5-HT,, receptors, especially those of nearby mesopontine cholinergic neurons. Because mesopontine cholinergic neurons are inhibited by postsynaptic 5-HT,, receptor activation (Luebke et al., 1992) , diffusion or forced ejection of 8-OH-DPAT into this area would act to inhibit the REM sleep-promoting neurons and hence reduce REM sleep percentage.
Animal preparation. Twelve adult cats weighing -3 kg were preanesthetized with a 0.1 ml/kg dose of a 1O:l mixture of ketamine hydrochloride (100 mg/ml) and acepromazine maleate (10 mg/ml). Sodium pentobarbital was administered intravenously (30 mgikg) to obtain and maintain deep surgical anesthesia. Cats were then stereotaxically implanted with electrodes to record EEG, electrooculogram (EOG), EMG, and dorsal lateral geniculate nucleus PGO wave activity. An intracerebral guide cannula (CMA lo/guide, Carnegie Medicine) was implanted 12 mm above the target to guide the probe to the implantation site, which had Berman atlas (Berman, 1968) coordinates of A 0.6, ML 0, DV -1. The guide tube and the inserted probe had an angle of angle of 30" from the vertical to allow the optimal sampling of the DRN while missing the bony tentorium. After surgery the animals were allowed to recover for 2 weeks. A CMA 10 probe from Carnegie Medicine was used; this had a polycarbonateipolyether copolymer membrane with 20,000 Da molecular weight cutoff, a 500 pm diameter, and a 1 mm tip length. The small size of the probe tip is important because it minimized the diffusion of the drug delivered outside the target zone. The probe was inserted 20-24 hr before starting the experiment to allow for disturbances of the extracellular environment secondary to probe insertion to subside. Before probe insertion, the ependyma of the aqueduct was perforated using a sharp stilette to avoid mechanical damage of the probe en route to the DRN.
Cats were housed individually under conditions of constant light with ad libitum access to food and water and were maintained at constant room temperature (23°C). Experiments were conducted in a electrically shielded, sound-attcnuatcd chamber that had the same temperature and light conditions as the animals' home cages. The experiment started by perfusing the probe with artificial CSF (ACSF = NaCl 147 mM, KCI 4 mM, CaCI, 2.3 mM, pH 7.2) at a flow rate of I.5 plimin using a microdialysis pump (CMA 100, Carnegie Medicine). To record behavioral states the animals were connected to a polygraph (Grass model 6A); dialysis perfusate was collected via a dual channel microdialysis swivel (Instech Laboratories, PA) incorporated into an electrical swivel (Airflyte Electronics, Bayonne, NJ). Each sample was taken over a 5 min period (at 1.5 &min = 7.5 @ample), and the time delay attributable to the dead volume of the system (fluid contained in the output perfusate tubing, the swivel and the probe) was taken into account in correlating neurochemical readings with the EEG recording of behavioral state.
5-HT analysis. Samples were injected in a microbore HPLC system (Bioanalytical Systems, West Lafayette, IN) (10 ~1 loop, Rheodyne injector model 9125-087A) coupled to an electrochemical detector (LC-44, Bioanalytical Systems). Separation was achieved using a SepStik microbore column ODS (3 Frn particle size) and a mobile phase consisting of ethylenediaminetetraacetic acid 0.185 gm/l, sodium octyl sulfate 0.15 gm/l, sodium phosphate 0.1 M, acetonitrile 12%, pH -5. The detection limit for 5-HT in the dialysate was -0.5 fmol/sample.
Chromatographic data were recorded and concentrations determined by a Shimadzu (CR3A, Kyoto, Japan) integrator using an external standard calibration curve. 5-HT in dialysis solutions was identified by comparing retention times of 5-HT standards (5-HT, Sigma, St. Louis, MO) to the retention times of sample peaks identified as 5-HT (matched within 0.04 min). As described previously (Portas and McCarley, 1994) , we also confirmed the identical retention time of the putative sample 5-HT peak and that of a known amount of 5-HT added to the dialysate sample. With placements of the probe in the aqueduct, no 5-HT signal was detected.
Statistical procedures. The main hypothesis was that 8-OH-DPAT perfusion would produce an augmentation in REM sleep, compared with control ACSF perfusion, and that this reduction in REM sleep would be accompanied by a reduction in DRN 5-HT release. This hypothesis was evaluated by t tests performed on log,,,-transformed data (to stabilize variance), and the significance levels of tests of this hypothesis, and other, nonpredicted changes in state and 5-HT release were indicated by conservative two-tail probability measures.
Experimental protocol. Animals were connected to a polygraph and ACSF perfusion started at least 1 hr before sampling began. Multiple samples were obtained from the DRN across behavioral states during the period 12 noon to 10 P.M. The 2 hr between 6 P.M. and 8 P.M. was used as a control time window for determining baseline W, SWS, and REM values. This period of time offered conditions similar to the ones obtained during the S-OH-DPAT perfusion, that is, same experimental day, same phase of circadian rhythm, and the presence of the microdialysis probe in DRN. At 8 P.M. the ACSF perfuiate was replaced by onk containing ACSF + 8-OH-DPAT, 10 EM. The drug was continuouslv oerfused for 2 hr (approximately 8 P.M. tb 10 P.M., wyth perfusion alway's beginning in waking). For comparison of 5-HT levels during the same state (waking), at least two samples/animal were obtained in the 2 hr of the baseline Portas et al. l &OH-DPAT in DRN Enhances REM Sleep and Reduces DRN 5-H-r control period (before S-OH-DPAT) and also during the 2 hr of &OH-DPAT perfusion. At 10 P.M. perfusion with ACSF alone was resumed and the animal was recorded for 1 more hr before ending the experiment. In vitro dialysis test procedure. In vitro perfusion was used to test the bidirectional dialyzing properties of the probe for both 5-HT and &OH-DPAT. First, the recovery of 5-HT by each probe was calculated. To do so each probe was immersed in a liquid containing a known amount of 5-HT and the ACSF perfusion started. The flow rate used was identical in both in vivo and in vitro conditions. Under these circumstances the average relative recovery for 5-HT was 12% (for an extensive review of microdialysis technique, see Robinson and Justice, 1991) . Secondly, the diffusion of 8-OH-DPAT through the probe was evaluated. The drug was introduced at a concentration of 10 pM in ACSF. Diffusion from the probe into the surrounding 1 ml volume of ACSF was then examined by assaying 8-OH-DPAT using HPLC electrochemical detection analysis.
Histology. For histological verification of the probe placement, animals were killed under pentobarbital anesthesia. The brains were perfused via the ascending aorta with 300 ml of ice-cold saline followed by 2% formaldehyde in 0.1 M phosphate buffer. The brains were then blocked, placed overnight in fixative, and transferred to 15% sucrose, 0.1 M phosphate buffer until equilibration. The brainstem was isolated, and sections were cut at 40 pm thickness on a freezing microtome. One series of sections (one-in-four) was stained with cresyl violet for histology. In two of the five cats with 8-OH-DPAT perfusion in the DRN, one-in-four series of sections were processed for 5-HT immunohistochemistry (polyclonal5-HT antibody raised in rat, Eugene Tech. International, Ramsey, NJ) to verify the placement of the probe among 5-HT-containing neurons.
Of the 12 animals prepared, 5, all with probes histologically localized to the DRN, were used to measure the effects of S-OH-DPAT nerfusion in this region (all 5 had behavioral measures, 4 had simultaneous determination of extracellular 5-HT); 3 animals had probes localized to the aqueduct and were used as controls; and 1 animal had the probe localized in the tegmentum but outside the raphe. The three remaining animals had DRN-localized probes: two were used for low calcium perfusate experiments and one was used for tetrodotoxin (TTX) perfusion.
RESULTS
All animals had histology for localization of the probe tip, with perfusion performed 2-6 d after each experiment. In each of the five cases described here as DRN perfusion, the probe tip was found to be located within the DRN and immunohistochemistry showed this to be within a field of serotonergic neurons (see Fig.  1 ). Chromatograms showing 5-HT level alterations during each polygraphically defined behavioral state and during &OH-DPAT perfusion are illustrated in Figure 2 . This figure also shows that the retention times of the 5-HT peaks were nearly identical in all chromatograms, indicating detection of the same compound. Note that there was a clear ordering of amplitudes of the 5-HT peak during the spontaneously occurring behavioral states: W > SWS > REM. This figure also shows that, compared with spontaneous waking, perfusion with &OH-DPAT produced a marked reduction in levels of 5-HT during the same polygraphically defined state.
Overview of experimental paradigm and effects of 8-OH-DPAT pet-Fusion
The time course of DRN 5-HT levels and behavioral state before and during addition of 10 PM 8-OH-DPAT to the microdialysis perfusate are illustrated for a typical experiment in Figure 3 . Examination of this figure shows that, during the 2.75 hr before addition of 8-OH-DPAT, the spontaneously occurring behavioral state percentages were: REM sleep = 6%, SWS = 16%, and W = 78%. Note also that these spontaneous states showed a clear correspondence of relatively high levels of 5-HT (>2 fmo1/7.5 ~1 dialysate sample) with the W state, whereas SWS and REM had lower levels. After addition of S-OH-DPAT to the perfusate, there was a large change in both the percentages of the behavioral states and also in the level of 5-HT. Throughout the perfusion, the DRN 8-OH-DPAT pe@sion increased REM sleep As illustrated in Figure 5 , perfusion of 8-OH-DPAT in the DRN produced a strong effect on behavioral state distribution. As predicted, the experimental condition, compared with the control condition, showed a statistically significant threefold increase of REM sleep, from 10.6 ? 2.34% (control condition, mean ? SEM) to 30.6 t 7.16% (during 8-OH-DPAT perfusion) of total recorded time (p < 0.05, paired t test, t = 3.18, 4 df, two-tailed).
REM sleep onset was usually -10 min after drug perfusion began, when 8-OH-DPAT concentration was still very low in the DRN.
Although W time fell from 54.3 i 11.78% (control condition) to 33.8 + 12% (during 8-OH-DPAT perfusion), this was not statistically significant (p = 0.274, paired t test, t = 1.27, 4 df, twotailed, five animals). As shown in Figure 5 , SWS percentage was virtually unchanged (p = 0.702, t = 0.41, 4 df, two-tailed, 5 animals).
8-OH-DPAT pe$usion and fine-grain analyses of behavioral state
Because 5-HT has long been suspected of having a suppressive effect on PGO wave activity over and above that postulated for the REM state as a whole (see review in Steriade and McCarley, 1990 ) the number of PGO waves occurring in 1 min sample periods (randomly selected, manually counted) of natural REM was compared with the number of PGO waves occurring in 1 min sample periods (randomly selected) of REM sleep during g-OH-DPAT perfusion into the DRN (n = 5 samples from two animals). The apparent increase of PGO waves was proportionate to the increase in the entire REM sleep state duration. Nor was there any difference in the number of PGO spikes in the 2 min before REM sleep onset (transition period) before and during 8-OH- DPAT perfusion (data not shown). With respect to motor activity, it was our impression that activity was less during waking after 8-OH-DPAT than spontaneous waking (Fig. 2 has less movement artifact in waking after 8-OH-DPAT). However, because this study was focused on sleep, we did not rigorously quantify motor activity. We attempted to evaluate for differences in DRN 5-HT levels during SWSl and SWS2; however, we were unable to obtain sufficient 5 min continuous samples of SWSl and SWS2 and hence did not include SWSl and SWs2 in the analyses of this study. Effects of 8-OH-DPAT perfusion at non-DRN sites Aqueductal &OH-DPAT pe$sion did not increase REM To investigate the specificity of the behavioral effects of DRN perfusion, in three animals 8-OH-DPAT was perfused into the aqueduct. As illustrated in Figure 6 , the effects were quite different than with DRN perfusion. First, REM was not increased but was nonsignificantly decreased (p = 0.69, paired t test, t = 0.54, 2 df, 3 animals). With aqueductal perfusion there was a trend level increase in wakefulness, from control values of 56.3 ? 5.6% to 84 5 8.09% 0, = 0.08, paired t test, t = 3.36, two tailed, 2 df, 3 animals). Aqueductal perfusion also produced a trend level decrease in SWS from control values of 36.6 ? 3.93% to 14.7 ? 7.69% (p = 0.10, paired t test, t = 2.85, 2 df, 3 animals). (Fig. 5) , there is no REM increase, and there is a trend for an increase in IV and a reduction in SWS. Error bars are SEM.
Perfusion of 8-OH-DPAT in the tegmentum ventral to DRN did not affect behavioral state
In one case, 8-OH-DPAT was perfused 4 mm ventral to DRN. Under these conditions no change in behavioral state were observed (data not shown).
Estimation of 8-OH-DPAT delively: an "in vitro " approximation
To obtain a rough order of magnitude estimate of the quantity of 8-OH-DPAT perfused through the probe over the 2 hr period, we tested in vitro the diffusion of 8-OH-DPAT (10 pM concentration) into a static 1 ml of ACSF surrounding the probe. The concentration of the drug in the surrounding medium rose over the 2 hr to a maximal value of 1.7 PM (-500 @ml 8-OH-DPAT). Because 1 ml is probably an overgenerous estimate of the true (but unknown) extracellular compartment volume, the figure of 500 ng of 8-OH-DPAT delivery is likely an overestimate (Fig. 7) . Similarly, we consider the extracellular concentration only an order of magnitude estimate. (We note that in vivo diffusion of the drug will be dependent on several factors, including the multicompartmental gradient effect, that are currently unknown.) The in vitro quantification of 8-OH-DPAT diffusion did verify the bidirectional dialyzing property of the microdialysis probes (essential for the experiment) and appears to offer an order of magnitude estimate of the amount of drug delivered in the DRN. We note that the amount obtained is of the same order of magnitude as the physiologically specific 8-OH-DPAT concentrations generally used in in vitro electrophysiological studies of dorsal raphe neurons in the rat (Hodgkiss et al., 1992 , 10 pM; Penington et al., 1993, 0 .1 PM; Williams et al., 1988 , 1 nM to 1 FM).
Calcium-and action potential activity-dependent 5HT release in the DRN
In previous studies neurotransmitter release estimated by in vivo microdialysis has been reported to be dependent on the presence of Cazf ions in the ACSF (Carboni and Di Chiara, 1989) . We therefore examined the effects of 0 mM Cazt in the ACSF on 5-HT release within the DRN. This procedure reduced 5-HT release to -20% of baseline output. 5-HT levels returned to control values -30 min after the replacement of Cazf-free ACSF with normal ACSF (n = 2 animals, Fig. 8 ). During this experiment 0 30 60 90 120 TIME (minutes) Figure 7 . In vitro measurements of 8-OH-DPAT concentration outside the microdialysis probe as a function of perfusion duration (perfusate concentration of 10 pM, external ACSF volume of 1 ml). 8-OH-DPAT concentration was 0.17 pM after 30 min, 0.5 pM after 60 min, 1 PM after 90 min, and a maximal concentration of 1.7 pM was achieved after 120 min.
no polygraphic recording was performed. We also investigated the effect of TTX, a highly specific Nat channel blocker, on S-HT release. In one animal, perfusion of TTX (0.5 PM) reduced 5-HT release to 40% of basal levels over a period of 80 min. 5-HT release was still reduced even after a 3 hr washout period, corresponding to the observed long duration of TTX activity when administered in vivo (Kao, 1966) . 
DISCUSSION
The data of the present study support the hypothesis that DRN serotonergic activity suppresses REM sleep (McCarley and Hobson, 197.5; McGinty and Harper, 1976; McCarley and Massaquoi, 1992) . Inhibition of DRN serotonergic neural activity via microdialysis-perfused &OH-DPAT, a selective 5-HT,, agonist, produced a threefold increase in the percentage of REM sleep. This behavioral increase in REM sleep was paralleled by a concomitant and consistent decrease in simultaneously measured extracellular DRN 5-HT levels in the DRN, which decreased to -59% of baseline levels, from -4 fmolisample in baseline waking to -2 fmol/sample in the same state during S-OH-DPAT perfusion.
We hypothesize that this DRN S-OH-DPAT-induced increase in REM sleep was mediated by a decrease in discharge levels of serotonergic DRN neurons and a resulting decrease in levels of 5-HT at DRN projections to mesopontine cholinergic neurons. Before discussing the role of mesopontine cholinergic neurons, we first cite three lines of evidence supporting a three-way parallelism among: DRN (presumptively) serotonergic neuronal discharge, and levels of 5-HT, both at distant projection sites of DRN and also within the DRN. (1) During naturally occurring sleep-wake cycles changes in discharge rate of DRN serotonergic (W > SWS > REM sleep) parallel changes in the level of DRN 5-HT (Portas and McCarley, 1994 , and confirmed by the present study). (2) During naturally occurring sleep-wake cycles, 5-HT levels at distant DRN projection sites in cats (Wilkinson et al., 1991) and rats (Auerbach et al., 1989 , Imeri et al., 1994 have the same W > SWS > REM sleep ordering as the discharge rates of DRN serotonergic neurons and of DRN 5-HT levels. (3) 8-OH-DPAT, a specific 5-HT,, agonist known to inhibit DRN serotonergic neuronal discharge, when delivered to the DRN, reduces 5-HT release both at distant DRN projection sites (Bonvento et al., 1992 , in the rat), and also within the DRN (the present study). What might mediate this three-way parallelism? At DRN distant projection sites, action potential-induced axonal release most likely accounts for the parallels in changes of discharge rate and 5-HT levels. A similar axonal release mechanism could account for the parallelism of discharge rates and 5-HT levels in the DRN, because there are recurrent axonal collaterals (Sprouse and Aghajanian, 1987) and recent in vitro experiments (O'Connor and Kruk, 1992) have demonstrated that application of 8-OH-DPAT to brain slices containing the DRN produced a concentrationdependent reduction in stimulation-induced release of DRN 5-HT. However, there are data in the rat indicating the possibility of nonaxonal (somatodendritic) 5-HT release (Adell et al., 1993) . If somatodendritic 5-HT release were to occur concomitantly with axonal action potentials, as might occur with either backpropagation of axonal action potentials or with forward propagation of dendritic spikes (Stuart and Sakmann, 1994) this also could account for the observed coupling.
With respect to the DRN projections likely to be involved in the REM sleep effects, there is now considerable evidence supporting the importance of mesopontine cholinergic neurons in REM generation. This includes anatomical evidence of projection to the pontine reticular formation (PRF, Mitani et al., 1988) , a zone containing effector neurons for many of the phenomena of REM sleep and where injections of cholinergic agonists produce a state mimicking REM sleep (see review in Steriade and McCarley, 1990) . Furthermore, there is evidence in cats that ACh release in PRF derives from mesopontine cholinergic neurons (Lydic and Baghdoyan, 1993) and recently it has been shown in cats that ACh release is enhanced in PRF during naturally occurring REM sleep (Leonard and Lydic, 1995) , as well as in more dorsal and rostra1 pontine regions (Kodama et al., 1990) .
Other data support our hypothesis of DRN serotonergic inhibition of mesopontine cholinergic neurons. Anatomical data indicate DRN serotonergic projections to mesopontine cholinergic neurons (Honda and Semba, 1994) and in vitro physiological experiments demonstrate that 5-HT inhibits identified mesopontine cholinergic neurons in the rat (Luebke et al., 1992; Leonard and Llinas, 1994) . Moreover, S-OH-DPAT, but not a 5-HT, agonist without specificity for the 5-HT,, receptor subtype, suppresses REM and PGO wave occurrence in in vivo microinjections into the PPT in cats (Sanford et al., 1994) . Thus, it is plausible that suppression of DRN activity might disinhibit mesopontine cholinergic neurons and thereby increase REM sleep. However, only in viva studies of REM sleep effects are capable of addressing the question of whether the demonstrated serotonergic inhibition is sufficiently strong so that its reduction would significantly affect REM sleep. The present data suggest that DRN activity is indeed important in REM suppression, and, together with anatomical and both in vitro and in viva physiological data, are consistent with the mediation of this REM suppression via DRN serotonergic projections to mesopontine cholinergic neurons. Historically, the question of DRN inhibition of REM sleep has been an important but unresolved conundrum for some 20 years: the hypothesis of monoaminergic disinhibition leading to REM sleep was proposed in McCarley and Hobson's theoretical paper (1975) and in McGinty and Harper's empirical paper (1976) .
From a methodological point of view, the present data suggest the utility and practicality of using microdialysis to apply pharmacological agents to nuclei putatively involved in REM sleep regulation, and thereby to offer empirical tests of hypothesized mechanisms. The contrast of behavioral effects of 8-OH-DPAT when administered within the DRN and when administered at other brain sites and systemically also seems worthy of emphasis. The effects of aqueductal administration are compatible with the results of previous systemic administration studies in cats (Adrien and Hamon, 1989) and rats (De St. Hilaire-Kafi et al., 1987; Monti et al., 1990) . A potential problem with large probes placed "in the vicinity" of the raphe (Adell and Artigas, 1991: in rats, dialyzing membrane length = 3.5 mm) is that the zone sampled almost certainly will include areas that are very heterogeneous with respect to intrinsic and afferenting neurotransmitters; these zones include the LDT tegmental nucleus (Luebke et al., 1992; Semba, 1993; Honda and Semba, 1994 ) the locus coeruleus (Pickel et al., 1977) and the reticular formation (Semba, 1993) , zones in which 5-HT would produce quite different results than in DRN. Voltametric measurements of 5-hydroxyindoles during the sleep-wake cycle (Houdouin et al., 1991) appear to have a limited specificity because the primary signal comes from 5-HIAA, the level of which is not closely correlated with that of 5-HT, as shown by Auerbach et al. (1989) and Crespi et al. (1990) and by our own data (Portas and McCarley, 1994) .
We note that the present study primarily examined REM sleep effects and was not designed to measure motor behavior quantitatively; we thus could not test a hypothesized link of motor behavior and serotonergic activity (Jacobs and Fornal, 1993) . Nor were there sufficient sample periods of pure SWSl or SWS2 (light and deep SWS, respectively) to allow a quantitative measure of 5-HT levels, and we consequently did not include these variables in the present study. The concentrations of S-OH-DPAT in the present study are much lower than those shown to induce hypothermia (Higgins et al., 1988; Bill et al., 1991) , which can modulate behavioral state (McGinty and Szymusiak, 1990) . Because norepinephrine, like 5-HT, has been shown to inhibit mesopontine cholinergic neurons in vitro (Williams and Reiner, 1993) and norepinephrinergic locus coeruleus neurons show the same REM sleep-related discharge rate decrease as DRN neurons, the present data suggest that analogous microdialysis experiments might be useful in locus coeruleus, using an (~z We conclude that the REM enhancement after S-OH-DPAT microdialysis represents the behavioral response dependent on a reduction in serotonergic neuronal discharge activity within the DRN and on a concomitant reduction in DRN axonal 5-HT release. Given the data indicating 5-HT inhibition of mesopontine cholinergic neurons and the their role in REM sleep (see above), we think it is likely that the increase in REM sleep is mediated by a disinhibition of cholinergic REM-promoting mesopontine neurons. We note that determination of a reduction in extracellular 5-HT in. the mesopontine cholinergic zone in the course of our experimental protocol of control and S-OH-DPAT infusion would offer somewhat more direct evidence, although there is little reason to suspect that there would not be a REM sleep-related reduction in extracellular 5-HT in the mesopontine zone, given its presence in other DRN projection targets (and we also note the considerable technical difficulty of simultaneous placement of two microdialysis probes in the DRN and in the very nearly adjacent mesopontine region).
Overall, these experimental data support the postulate McCarley and Massaquoi, 1992 ) that the naturally occurring decrease in discharge rate of DRN monoaminergic neurons that occurs during spontaneous SWS and before REM sleep may act to disinhibit the mesopontine cholinergic neurons shown to be REM-active and thus promote the occurrence of REM sleep. As discussed in our theoretical paper (McCarley and Massaquoi, 1992) , this raises the question of what mechanisms lead to a decrease in discharge rate of DRN neurons. One possibility is increased activation of DRN GABAergic inhibitory interneurons (Nishikawa and Scatton, 1985; Nitz and Siegel, 1993) , although the mechanisms for this activation remain unknown. Another, and nonexclusive possibility, is that sustained activation of DRN somato-dendritic 5-HT,, receptors, as occurs with high DRN discharge levels during wakefulness, may produce a long-lasting inhibition through second messenger mechanisms (McCarley and Massaquoi, 1992) . We believe that the technical advantages of in viva microdialysis will continue to prove useful in unraveling these and other questions about the mechanisms of sleep cycle control.
